Medicare Part B Drug "Least Costly Alternative" Policy Rescinded By CMS
This article was originally published in The Pink Sheet Daily
Executive Summary
Policy had been used to limit expenditures for prostate cancer drugs and inhaled drugs for pulmonary disease.
You may also be interested in...
Drugs Not ‘On Radar’ For Medicare Coverage Review, Official Says
The director of Medicare’s coverage and analysis group says that, at the moment, no biopharma products are being considered for a national coverage determination. Another official says Medicare cannot use comparative effectiveness data in making reimbursement decisions.
Drugs Not ‘On Radar’ For Medicare Coverage Review, Official Says
The director of Medicare’s coverage and analysis group says that, at the moment, no biopharma products are being considered for a national coverage determination. Another official says Medicare cannot use comparative effectiveness data in making reimbursement decisions.
IPAB Will Make CMS More Relevant In Parallel Reviews With FDA, Former Official Gottlieb Predicts
BALTIMORE – Decisions by the soon-to-be-created Independent Payment Advisory Board could make CMS participation in parallel review of drugs with FDA much more meaningful than it would otherwise be, assuming the health care reform law remains intact, former CMS and FDA official Scott Gottlieb said.